Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY

Delayed Quote. Delayed  - 06/24 10:00:04 pm
54.31 USD   -4.64%
06/23 ALNYLAM PHARMAC : Supports Greater Boston and Norton Communities wit..
06/23 ALNYLAM PHARMAC : Supports Greater Boston and Norton Communities wit..
06/17 ALNYLAM PHARMAC : Biotechnology Equities Technical Review -- Geron, ..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/20/2016 06/21/2016 06/22/2016 06/23/2016 06/24/2016 Date
56.64(c) 55.78(c) 56.14(c) 56.95(c) 54.31 Last
863 961 2 087 463 996 117 789 183 1 812 647 Volume
+1.20% -1.52% +0.65% +1.44% -4.64% Change
More quotes
Financials ($)
Sales 2016 41,7 M
EBIT 2016 -436 M
Net income 2016 -421 M
Finance 2016 583 M
Yield 2016 -
Sales 2017 58,0 M
EBIT 2017 -478 M
Net income 2017 -464 M
Finance 2017 455 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 103x
EV / Sales2017 76,0x
Capitalization 4 861 M
More Financials
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which discovery, development and commercialization of RNAi therapeutics.It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases.The... 
More about the company
Surperformance© ratings of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on ALNYLAM PHARMACEUTICALS, I
06/23 ALNYLAM PHARMACEUTICALS : Supports Greater Boston and Norton Communities with it..
06/23 ALNYLAM PHARMACEUTICALS : Supports Greater Boston and Norton Communities with it..
06/17 ALNYLAM PHARMACEUTICALS : Biotechnology Equities Technical Review -- Geron, Merr..
06/16 ALNYLAM PHARMACEUTICALS : Initiates Phase 1 Clinical Trial for ALN-TTRsc02, an I..
06/15 ALNYLAM PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form ..
06/11 ALNYLAM PHARMACEUTICALS : Reports Initial ALN-CC5 Results in Patients with Parox..
06/10 Edinburgh Worldwide Investment Trust Boosted By Tesla And MarketAxess
06/09 ALNYLAM PHARMACEUTICALS : Initiates Phase 1 Clinical Trial for ALN-TTRsc02, an I..
06/03 Biotechnology Stocks Giving Back Ground After Recent Gains
06/03 ALNYLAM PHARMACEUTICALS : to Webcast Conference Call Discussing ALN-CC5 Phase 1/..
More news
Sector news : Biotechnology & Medical Research - NEC
02:36p MEDIVATION : Glass Lewis Recommends Medivation's Stockholders Support the Compan..
02:31p MEDIVATION : Glass Lewis Recommends Medivation’s Stockholders Support the ..
12:46p QUINTILES : Introduces Continuous Glucose Monitoring Services to Improve Diabete..
12:11a MEDIVATION : Sends Letter to Stockholders to Set the Record Straight on Sanofi's..
06/23 MEDIVATION : Sends Letter to Stockholders to Set the Record Straight on Sanofi&r..
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
06/23 Amyloidosis Pipeline Still Looks To Alnylam For Answers
06/22 Alnylam Readouts Offer 2017-2018 Catalysts
06/20 REGENERON GENERATES NEGATIVE ALPHA : Buy, Sell Or Hold?
06/03 BIOTECHNOLOGY : Ready To Move Higher - Much Higher
06/02 The Medicines Company hits enrollment target in mid-stage study of RNAi thera..
Advertisement
Chart ALNYLAM PHARMACEUTICALS, I
Duration : Period :
Alnylam Pharmaceuticals, I Technical Analysis Chart | ALNY | US02043Q1076 | 4-Traders
Full-screen chart
Technical analysis trends ALNYLAM PHARMACEU...
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions